

WHAT IS CLAIMED IS:

1. A remedy for interstitial pneumonia, comprising at least one, or two or more kinds of an interleukin 18 inhibitor and/or an interleukin 2 inhibitor as an active ingredient.
2. A remedy for interstitial pneumonia, comprising an interleukin 18 inhibitor as an active ingredient.
3. The remedy for interstitial pneumonia according to claim 1 or 2, wherein the inhibitor is a substance which inhibits conversion of a precursor of interleukin 18 into an activated one.
4. The remedy for interstitial pneumonia according to claim 3, wherein the inhibitor is an inhibitor of cysteine protease.
5. The remedy for interstitial pneumonia according to claim 4, wherein the inhibitor of cysteine protease is an interleukin 1 β -converting enzyme inhibitor.
6. The remedy for interstitial pneumonia according to claim 1 or 2, wherein the inhibitor is an interleukin 18-binding protein.

7. The remedy for interstitial pneumonia according to claim 1 or 2, wherein the inhibitor is a monoclonal antibody specific for interleukin 18.

8. The remedy for interstitial pneumonia according to claim 1 or 2, wherein the inhibitor is a monoclonal antibody specific for a receptor of interleukin 18.

9. The remedy for interstitial pneumonia according to claim 7 or 8, wherein the monoclonal antibody is an antibody derived from mammal.

10. The remedy for interstitial pneumonia according to claim 7 or 8, wherein the monoclonal antibody is a chimera antibody.

11. The remedy for interstitial pneumonia according to claim 7 or 8, wherein the monoclonal antibody is a humanized antibody.

12. A remedy for interstitial pneumonia, comprising an interleukin 2 inhibitor as an active ingredient.

13. The remedy for interstitial pneumonia according to claim 1 or 12, wherein the inhibitor is a monoclonal antibody specific for interleukin 2.

14. The remedy for interstitial pneumonia according to claim 1 or 12, wherein the inhibitor is a substance which inhibits binding of interleukin 2 to an interleukin 2 receptor.

15. The remedy for interstitial pneumonia according to claim 14, wherein the substance, which inhibits binding of interleukin 2 to the interleukin 2 receptor, is an antibody or ligand bound to α chain, β chain and/or γ chain subunits of the interleukin 2 receptor.

16. The remedy for interstitial pneumonia according to claim 13 or 14, wherein the monoclonal antibody is an antibody derived from mammal.

17. The remedy for interstitial pneumonia according to claim 13 or 14, wherein the monoclonal antibody is a chimera antibody.

18. The remedy for interstitial pneumonia according to claim 13 or 14, wherein the monoclonal antibody is a humanized antibody.

19. The remedy for interstitial pneumonia according to claim 1 or 12, wherein the inhibitor is a substance which acts as an antagonist of interleukin 2.

20. The remedy for interstitial pneumonia according to claim 18, wherein the substance, which acts as the antagonist of interleukin 2, is an interleukin 2-diphtheria toxin conjugate.

21. A method of preparing an animal model of interstitial pneumonia, which comprises administering interleukin 18 and interleukin 2 to a rodent.

22. The method of preparing an animal model of interstitial pneumonia according to claim 21, wherein the rodent is a mouse.

23. A method of screening a remedy for interstitial pneumonia, which comprises using the animal model of interstitial pneumonia of claim 21 or 22.

24. A composition, comprising at least one kind of an interleukin 18 inhibitor and/or an interleukin 2 inhibitor.

25. A method for preparing an animal model of interstitial pneumonia, which comprises the steps of: administering interleukin 18 and interleukin 2 to a rodent; and preparing an animal model of interstitial pneumonia.

26. The method for preparing an animal model of interstitial pneumonia according to claim 25, wherein the rodent is a mouse.

27. A method for screening a remedy for interstitial pneumonia, which comprises the steps of: administering interleukin 18 and interleukin

2 to a rodent; preparing an animal model of interstitial pneumonia; and screening a remedy for interstitial pneumonia.

28. A method according to claim 27, wherein the rodent is a mouse.

29. A method for preventing or treating interstitial pneumonia, comprising the step of administering to a patient who is subject to interstitial pneumonia an effective amount of at least one kind of an interleukin 18 inhibitor and/or an interleukin 2 inhibitor.

30. A method for preventing or treating interstitial pneumonia, comprising the step of administering to a patient who is subject to interstitial pneumonia an effective amount of an interleukin 18 inhibitor.

31. A method for preventing or treating interstitial pneumonia, comprising the step of administering to a patient who is subject to interstitial pneumonia an effective amount of an interleukin 2 inhibitor.